Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, García-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681-93.
DOI: 10.1016/j.jhep.2021.11.018
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
DOI: 10.1038/s41572-020-00240-3
Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, et al. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021;11:1546-67.
DOI: 10.7150/thno.48662
Zhang N, Li Y. Receptor tyrosine kinases: biological functions and anticancer targeted therapy. MedComm (Beijing) 2023;4:e446.
DOI: 10.1002/mco2.446
Payo-Serafín T, Méndez-Blanco C, Fernández-Palanca P, Martínez-Geijo J, Reviejo M, Ortiz-de-Urbina JJ, et al. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Pharmacol Ther 2024;116:328-45.
DOI: 10.1002/cpt.3312
Da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis 2020;24:719-37.
DOI: 10.1016/j.cld.2020.07.012
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 2025;82:315-74.
Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther 2025;10:35.
DOI: 10.1038/s41392-024-02075-w
Sharma A, Seow JJW, Dutertre C-A, Pai R, Blériot C, Mishra A, et al. Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell 2020;183:377-394.e21.
DOI: 10.1016/j.cell.2020.08.040
Craig AJ, von Felden J, García-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139-52.
DOI: 10.1038/s41575-019-0229-4
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-905.
DOI: 10.1056/NEJMoa1915745
Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-96.
DOI: 10.1016/S1470-2045(18)30937-9
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023;402:1133-46.
DOI: 10.1016/S0140-6736(23)00961-3
Wei T, Zhang L-N, Lv Y, Ma X-Y, Zhi L, Liu C, et al. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget 2014;5:10307-17.
DOI: 10.18632/oncotarget.2537
Zhang T, Sun H-C, Xu Y, Zhang K-Z, Wang L, Qin L-X, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005;11:8557-63.
DOI: 10.1158/1078-0432.CCR-05-0944
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 2021;39:3002-11.
DOI: 10.1200/JCO.21.00163
Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172-9.
DOI: 10.1200/JCO.2013.54.3298
Yen C-J, Kim T-Y, Feng Y-H, Chao Y, Lin D-Y, Ryoo B-Y, et al. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018;7:165-78.
DOI: 10.1159/000486460
Cheng A-L, Kang Y-K, Lin D-Y, Park J-W, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-75.
DOI: 10.1200/JCO.2012.45.8372
Gao L, Wang X, Tang Y, Huang S, Hu C-AA, Teng Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res 2017;36:8.
DOI: 10.1186/s13046-016-0478-9
Cui G, Martín RC, Jin H, Liu X, Pandit H, Zhao H, et al. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. J Exp Clin Cancer Res 2018;37:136.
DOI: 10.1186/s13046-018-0781-8
Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012;131:2961-9.
DOI: 10.1002/ijc.27604
He X, Hikiba Y, Suzuki Y, Nakamori Y, Kanemaru Y, Sugimori M, et al. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci Rep 2022;12:8007.
DOI: 10.1038/s41598-022-12076-w
Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66.
DOI: 10.1200/JCO.2013.53.7746
Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
DOI: 10.1038/ng.3252
Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, et al. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol 2016;113:55-61.
DOI: 10.1002/jso.24086
Fu R, Jiang S, Li J, Chen H, Zhang X. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Med Oncol 2020;37:24.
DOI: 10.1007/s12032-020-01350-4
Ma Y, Liu X, Tang X. ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma. Am J Transl Res 2023;15:896-913.
Yau T, Kaseb A, Cheng A-L, Qin S, Zhu AX, Chan SL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol 2024;9:310-22.
DOI: 10.1016/S2468-1253(23)00454-5
Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect with the Use of Tivantinib? Front Immunol 2021;12:731527.
DOI: 10.3389/fimmu.2021.731527
Eckel F, Von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005;69:363-71.
DOI: 10.1159/000089990
Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021;15:621-9.
DOI: 10.1007/s12072-021-10171-0
Zhang C-S, Zeng Z-M, Zhuo M-Y, Luo J-R, Zhuang X-H, Xu J-N, et al. Anlotinib Combined with Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study. Oncologist 2023;28:e1239-47.
DOI: 10.1093/oncolo/oyad169
Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261-73.
DOI: 10.1016/S1470-2045(22)00541-1
Duke ES, Bradford D, Marcovitz M, Amatya AK, Mishra-Kalyani PS, Nguyen E, et al. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors. Clin Cancer Res 2023;29:3573-8.
DOI: 10.1158/1078-0432.CCR-23-0459
Kim J, Bradford D, Larkins E, Pai-Scherf LH, Chatterjee S, Mishra-Kalyani PS, et al. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clin Cancer Res 2021;27:5452-6.
DOI: 10.1158/1078-0432.CCR-21-0967
Jiang X, Ge X, Huang Y, Xie F, Chen C, Wang Z, et al. Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies. Cancer Lett 2025;613:217472.
DOI: 10.1016/j.canlet.2025.217472
Lu Y, Shen H, Huang W, He S, Chen J, Zhang D, et al. Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discov 2021;7:359.
DOI: 10.1038/s41420-021-00747-y
Chen L, Li Y, Chen Y. KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2. IScience 2023;26:106914.
DOI: 10.1016/j.isci.2023.106914
Younis NS, Ghanim AMH, Saber S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci Rep 2019;9:19095.
DOI: 10.1038/s41598-019-55666-x
Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, et al. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clin Cancer Res 2018;24:4650-61.
DOI: 10.1158/1078-0432.CCR-17-3588
Shi Y, Cui D, Xia L, Shi D, Jin G, Wang S, et al. Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial. Signal Transduct Target Ther 2024;9:359.
DOI: 10.1038/s41392-024-02085-8
Sun Y, Zhang H, Meng J, Guo F, Ren D, Wu H, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. Cell Rep 2022;40:111194.
DOI: 10.1016/j.celrep.2022.111194
Hou W, Bridgeman B, Malnassy G, Ding X, Cotler SJ, Dhanarajan A, et al. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatol Commun 2022;6:1786-802.
DOI: 10.1002/hep4.1928
Miyazaki K, Morine Y, Xu C, Nakasu C, Wada Y, Teraoku H, et al. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells 2023;12.
DOI: 10.3390/cells12040612
Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 2017;38:899-907.
DOI: 10.3892/or.2017.5722
Wang T, Qin Z-Y, Wen L-Z, Guo Y, Liu Q, Lei Z-J, et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells. Cell Death Differ 2018;25:2086-100.
DOI: 10.1038/s41418-018-0095-6
Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, et al. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett 2023;559:216122.
DOI: 10.1016/j.canlet.2023.216122
Wu J, Chai H, Li F, Ren Q, Gu Y. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Life Sci 2020;260:118406.
DOI: 10.1016/j.lfs.2020.118406
Huang M, Chen C, Geng J, Han D, Wang T, Xie T, et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett 2017;398:12-21.
DOI: 10.1016/j.canlet.2017.03.038
Lippolis C, Refolo MG, D’Alessandro R, Carella N, Messa C, Cavallini A, et al. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res 2015;34:90.
DOI: 10.1186/s13046-015-0210-1
Cai W, Ma Y, Song L, Cao N, Gao J, Zhou S, et al. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways. BMC Cancer 2023;23:87.
DOI: 10.1186/s12885-023-10561-7
Refolo MG, D’Alessandro R, Lippolis C, Carella N, Cavallini A, Messa C, et al. IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines. Oncotarget 2017;8:103465-76.
DOI: 10.18632/oncotarget.21403
Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, et al. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol 2019;10:e00056.
DOI: 10.14309/ctg.0000000000000056
Song Y-G, Yeom K-M, Jung EA, Kim SG, Kim YS, Yoo J-J. Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis. Liver Cancer 2024;13:590-600.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24:1399-410.
DOI: 10.1016/S1470-2045(23)00469-2
Hsu Y-C, Lin P-T, Teng W, Hsieh Y-C, Chen W-T, Su C-W, et al. Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers (Basel) 2024;16.
DOI: 10.3390/cancers16203458
Kelley RK, Rimassa L, Cheng A-L, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:995-1008.
DOI: 10.1016/S1470-2045(22)00326-6
Kim H-D, Jung S, Lim HY, Ryoo B-Y, Ryu M-H, Chuah S, et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med 2024;30:699-707.
DOI: 10.1038/s41591-024-02824-y
Número de descargas:
45
Número de visitas:
22
Citas:
0
